Friday, 16 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 2, 2026

$100 Dollar Loans Online With Same Day Instant Funding to Debit Card: RadCred Launches Direct Lenders-Only Emergency Cash Platform

View original at globenewswire.com
$100 Dollar Loans Online With Same Day Instant Funding to Debit Card: RadCred Launches Direct Lenders-Only Emergency Cash Platform Glendale, CA, Feb…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Financial surveys consistently show that a significant portion of adults would struggle to cover a small unexpected cost without borrowing or delaying payment

    80% confidence
  • A $100 loan is often sufficient to address short-term gaps between paychecks

    80% confidence
  • Demand is not for larger loans, but for timing - many borrowers only need a small amount to cover a short gap

    80% confidence
  • Benefits of $100 loans apply only when loans are used responsibly and repaid as agreed

    80% confidence
  • The $100 loan category addresses common timing gaps caused by everyday expenses such as fuel, utility payments, and medical co-pays

    80% confidence
  • These loans are structured for short-term use and are not positioned as long-term credit solutions

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com